131I Effective Half-Life and Dosimetry in Thyroid Cancer Patients
- 14 August 2008
- journal article
- Published by Society of Nuclear Medicine in Journal of Nuclear Medicine
- Vol. 49 (9), 1445-1450
- https://doi.org/10.2967/jnumed.108.052464
Abstract
(131)I treatment in thyroid cancer patients may induce side effects, including extrathyroidal cancer and leukemia. There are still some uncertainties concerning parameters that may influence the effective half-life of (131)I and the absorbed doses by extrathyroidal organs. Whole-body retention of radioiodine was measured in 254 patients, and repeated quantitative whole-body scans and measurements of the urinary excretion of (131)I were performed on 30 of these patients. The mean effective half-life (10.5 h) was shorter by 31%, with little difference between patients, in the 36 patients who received recombinant human thyroid-stimulating hormone than in the 218 patients who underwent thyroid hormone withdrawal (15.7 h). The residence times in the stomach and in the rest of the body were significantly shorter in patients who received recombinant human thyroid-stimulating hormone than in patients who underwent withdrawal, but the residence times were similar in the colon and bladder. In patients who undergo thyroid hormone withdrawal, the longer mean effective half-life is mainly due to delayed renal excretion of (131)I and results in dose estimates higher than the data in report 53 of the International Commission on Radiological Protection, which were obtained from healthy, euthyroid subjects.This publication has 18 references indexed in Scilit:
- Length and cost of hospital stay of radioiodine ablation in thyroid cancer patients: comparison between preparation with thyroid hormone withdrawal and thyrogenEuropean Journal of Nuclear Medicine and Molecular Imaging, 2008
- Defects in iodide metabolism in thyroid cancer and implications for the follow-up and treatment of patientsNature Clinical Practice Endocrinology & Metabolism, 2007
- Comparison of iodine uptake in tumour and nontumour tissue under thyroid hormone deprivation and with recombinant human thyrotropin in thyroid cancer patientsClinical Endocrinology, 2006
- 131I EFFECTIVE HALF-LIFE (Teff) FOR PATIENTS WITH THYROID CANCERHealth Physics, 2006
- European consensus for the management of patients with differentiated thyroid carcinoma of the follicular epitheliumActa Endocrinologica, 2006
- Management Guidelines for Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines TaskforceThyroid®, 2006
- Radioactive Iodine and the Salivary GlandsThyroid®, 2003
- Papillary and Follicular Thyroid CarcinomaThe New England Journal of Medicine, 1998
- Quality-of-Life Changes in Patients with Thyroid Cancer After Withdrawal of Thyroid Hormone TherapyThyroid®, 1997
- Radiation Dose to Patients from RadiopharmaceuticalsAnnals of the ICRP, 1987